These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18378635)

  • 1. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
    Remarque EJ; Faber BW; Kocken CH; Thomas AW
    Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.
    Kusi KA; Faber BW; Riasat V; Thomas AW; Kocken CH; Remarque EJ
    PLoS One; 2010 Nov; 5(11):e15391. PubMed ID: 21082025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.
    Kusi KA; Faber BW; Thomas AW; Remarque EJ
    PLoS One; 2009 Dec; 4(12):e8110. PubMed ID: 19956619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
    Giersing B; Miura K; Shimp R; Wang J; Zhou H; Orcutt A; Stowers A; Saul A; Miller LH; Long C; Singh S
    Infect Immun; 2005 Jul; 73(7):3963-70. PubMed ID: 15972483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
    Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
    PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation.
    Faber BW; Hellwig S; Houard S; Havelange N; Drossard J; Mertens H; Croon A; Kastilan R; Byrne R; van der Werff N; van der Eijk M; Thomas AW; Kocken CH; Remarque EJ
    PLoS One; 2016; 11(10):e0164053. PubMed ID: 27695087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
    Ouattara A; Mu J; Takala-Harrison S; Saye R; Sagara I; Dicko A; Niangaly A; Duan J; Ellis RD; Miller LH; Su XZ; Plowe CV; Doumbo OK
    Malar J; 2010 Jun; 9():175. PubMed ID: 20565971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
    Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
    Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
    Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
    Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
    Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
    PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
    Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
    Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.
    Dutta S; Dlugosz LS; Drew DR; Ge X; Ababacar D; Rovira YI; Moch JK; Shi M; Long CA; Foley M; Beeson JG; Anders RF; Miura K; Haynes JD; Batchelor AH
    PLoS Pathog; 2013; 9(12):e1003840. PubMed ID: 24385910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
    Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
    Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Faber BW; Yeoh LM; Kurtovic L; Mol WEM; Poelert M; Smits E; Rodriguez Garcia R; Mandalawi-Van der Eijk M; van der Werff N; Voorberg-van der Wel A; Remarque EJ; Beeson JG; Kocken CHM
    Vaccine; 2024 Mar; 42(7):1785-1792. PubMed ID: 38365484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
    Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
    Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.